Stocks and Investing Stocks and Investing
Thu, September 21, 2017
Wed, September 20, 2017
Tue, September 19, 2017
Mon, September 18, 2017
Fri, September 15, 2017
Thu, September 14, 2017
Wed, September 13, 2017
Tue, September 12, 2017
Mon, September 11, 2017
Fri, September 8, 2017
Thu, September 7, 2017

Gena Wang Initiated (BLUE) at Buy and Held Target at $151 on, Sep 7th, 2017


Published on 2024-10-25 22:40:49 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Initiated "bluebird bio, Inc." (BLUE) at Buy and Held Target at $151 on, Sep 7th, 2017.

Gena has made no other calls on BLUE in the last 4 months.



There are 5 other peers that have a rating on BLUE. Out of the 5 peers that are also analyzing BLUE, 4 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Josh Schimmer of "Evercore ISI Group" Initiated at Hold and Held Target at $102 on, Thursday, August 17th, 2017
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $105 on, Monday, August 7th, 2017
  • Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $109 on, Thursday, July 27th, 2017
  • Dane Leone of "BTIG" Downgraded from Strong Buy to Hold on, Friday, June 30th, 2017


This is the rating of the analyst that currently disagrees with Gena


  • Matthew Luchini of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $108 on, Tuesday, June 6th, 2017